Recent Advances in Hormonal Contraception

Overview

Journal F1000 Med Rep

Specialty General Medicine

Date 2010 Dec 22

PMID 21173872

Authors

Hw Raymond Li

Richard A Anderson

Affiliations

Soon will be listed here.

Abstract

This report reviews some of the new studies regarding new hormonal contraceptive formulations (e.g., Yaz, Qlaira(®), extended-cycle or continuous combined contraceptives, subcutaneous depot medroxyprogesterone acetate, and ulipristal acetate as an emergency contraceptive). Recent data on the relationship between hormonal contraceptive use and bone health are also reviewed.

References

Fruzzetti F, Bitzer J . Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2009; 81(1):8-15. DOI: 10.1016/j.contraception.2009.08.010. View

Guilbert E, Brown J, Kaunitz A, Wagner M, Berube J, Charbonneau L . The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health. Contraception. 2009; 79(3):167-77. DOI: 10.1016/j.contraception.2008.10.016. View

Lopez L, Kaptein A, Helmerhorst F . Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2009; (2):CD006586. DOI: 10.1002/14651858.CD006586.pub3. View

Hannaford P, Iversen L, Macfarlane T, Elliott A, Angus V, Lee A . Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. 2010; 340:c927. PMC: 2837145. DOI: 10.1136/bmj.c927. View

Martins S, Curtis K, Glasier A . Combined hormonal contraception and bone health: a systematic review. Contraception. 2006; 73(5):445-69. DOI: 10.1016/j.contraception.2006.01.003. View

Glasier A, Cameron S, Fine P, Logan S, Casale W, Van Horn J . Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis. Lancet. 2010; 375(9714):555-62. DOI: 10.1016/S0140-6736(10)60101-8. View

Vestergaard P, Rejnmark L, Mosekilde L . The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women. Contraception. 2008; 78(6):459-64. DOI: 10.1016/j.contraception.2008.07.014. View

Endrikat J, Milchev N, Kapamadzija A, Georgievska J, Gerlinger C, Schmidt W . Bleeding pattern, tolerance and patient satisfaction with a drospirenone-containing oral contraceptive evaluated in 3488 women in Europe, the Middle East and Canada. Contraception. 2009; 79(6):428-32. DOI: 10.1016/j.contraception.2008.12.007. View

Jain J, Jakimiuk A, Bode F, Ross D, Kaunitz A . Contraceptive efficacy and safety of DMPA-SC. Contraception. 2004; 70(4):269-75. DOI: 10.1016/j.contraception.2004.06.011. View

10.

Pikkarainen E, Lehtonen-Veromaa M, Mottonen T, Kautiainen H, Viikari J . Estrogen-progestin contraceptive use during adolescence prevents bone mass acquisition: a 4-year follow-up study. Contraception. 2008; 78(3):226-31. DOI: 10.1016/j.contraception.2008.05.002. View

11.

Westhoff C, Jain J, Milsom I, Ray A . Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 mL. Contraception. 2007; 75(4):261-7. DOI: 10.1016/j.contraception.2006.12.009. View

12.

Cheng L, Gulmezoglu A, Piaggio G, Ezcurra E, Van Look P . Interventions for emergency contraception. Cochrane Database Syst Rev. 2008; (2):CD001324. DOI: 10.1002/14651858.CD001324.pub3. View

13.

Curtis K, Martins S . Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006; 73(5):470-87. DOI: 10.1016/j.contraception.2005.12.010. View

14.

Vestergaard P, Rejnmark L, Mosekilde L . Fracture risk in very young women using combined oral contraceptives. Contraception. 2008; 78(5):358-64. DOI: 10.1016/j.contraception.2008.06.010. View

15.

Fenton C, Wellington K, Moen M, Robinson D . Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007; 67(12):1749-65. DOI: 10.2165/00003495-200767120-00007. View

16.

Kaunitz A, Darney P, Ross D, Wolter K, Speroff L . Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density. Contraception. 2009; 80(1):7-17. DOI: 10.1016/j.contraception.2009.02.005. View

17.

Anttila L, Kunz M, Marr J . Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive. Contraception. 2009; 80(5):445-51. DOI: 10.1016/j.contraception.2009.03.013. View